Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

INTRODUCTION: Ibrutinib (ibr) monotherapy and the combination of obinutuzumab plus chlorambucil (obi) are approved for previously untreated chronic lymphocytic leukemia (CLL). No trials directly comparing their efficacy are available. Therefore a matching-adjusted indirect comparison (MAIC) was perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Sanden, Suzy, Baculea, Simona, Diels, Joris, Cote, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504213/
https://www.ncbi.nlm.nih.gov/pubmed/28573505
http://dx.doi.org/10.1007/s12325-017-0564-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504213/
https://www.ncbi.nlm.nih.gov/pubmed/28573505
http://dx.doi.org/10.1007/s12325-017-0564-1

Ejemplares similares